open access

Vol 69, No 5 (2018)
Original Paper
Published online: 2018-08-03
Submitted: 2018-01-16
Accepted: 2018-01-22
Get Citation

Blood serum concentrations of gonadotropins and α-subunit in patients with gonadotropinomas in relation to the immunoreactivity of pituitary adenoma

Marek Pawlikowski (Łódź), Maria Jaranowska, Jolanta Fryczak, Maciej Radek, Jacek Świętosławski, Jolanta Kunert-Radek, Katarzyna Winczyk
DOI: 10.5603/EP.a2018.0049
·
Pubmed: 30074232
·
Endokrynologia Polska 2018;69(5):526-529.

open access

Vol 69, No 5 (2018)
Original Paper
Published online: 2018-08-03
Submitted: 2018-01-16
Accepted: 2018-01-22

Abstract

Introduction: Although active gonadotropin-secreting pituitary adenomas are considered very rare, the vast majority of pituitary tumours diagnosed as “non-functioning” express gonadotropins or their free β or α subunits. However, systemic investigations comparing the serum concentrations of follitropin (FSH), lutropin (LH), and α–subunit (αSU) before surgery with the immunoreactivity of the respective substances in the excised tumours are still lacking.

Material and methods: Immunostaining of FSH, LH, and αSU was compared in 43 surgically removed gonadotropin — expressing pitu­itary adenomas with serum concentrations of the above-mentioned substances before surgery in the same patients.

Results: The serum concentrations of FSH were elevated (> 11.6 mU/mL) in 8/12 (66.7%) cases of FSH-positive adenomas. By contrast, in FSH–negative tumours the elevation of FSH is absent. Moreover, only 1/25 (4%) patients with LH–positive adenoma had the elevated serum concentration of LH (51.5 mU/mL). The overproduction of LH was not observed in adenomas expressing free β LH or in LH-negative tumours. In patients with αSU-positive adenomas elevated serum levels of αSU were observed in 3/15 (20%) cases. No αSU elevations were observed in patients with αSU–negative adenomas. The mean serum FSH, LH, and αSU concentrations were higher in patients with FSH, LH, and/or αSU immunopositive tumours in comparison with immunonegative. However, the differences are not statistically significant.

Conclusions: Although “silent” gonadotropinomas constitute a frequent subtype of pituitary adenomas, the “active” subtype (i.e. manifesting by gonadotropin excess) are rare (approx. 4% of all pituitary adenomas). Gonadotropinomas are difficult to diagnose before surgery. The measurement of gonadotropins including αSU is needed but often not sufficient for presurgical diagnosis.

Abstract

Introduction: Although active gonadotropin-secreting pituitary adenomas are considered very rare, the vast majority of pituitary tumours diagnosed as “non-functioning” express gonadotropins or their free β or α subunits. However, systemic investigations comparing the serum concentrations of follitropin (FSH), lutropin (LH), and α–subunit (αSU) before surgery with the immunoreactivity of the respective substances in the excised tumours are still lacking.

Material and methods: Immunostaining of FSH, LH, and αSU was compared in 43 surgically removed gonadotropin — expressing pitu­itary adenomas with serum concentrations of the above-mentioned substances before surgery in the same patients.

Results: The serum concentrations of FSH were elevated (> 11.6 mU/mL) in 8/12 (66.7%) cases of FSH-positive adenomas. By contrast, in FSH–negative tumours the elevation of FSH is absent. Moreover, only 1/25 (4%) patients with LH–positive adenoma had the elevated serum concentration of LH (51.5 mU/mL). The overproduction of LH was not observed in adenomas expressing free β LH or in LH-negative tumours. In patients with αSU-positive adenomas elevated serum levels of αSU were observed in 3/15 (20%) cases. No αSU elevations were observed in patients with αSU–negative adenomas. The mean serum FSH, LH, and αSU concentrations were higher in patients with FSH, LH, and/or αSU immunopositive tumours in comparison with immunonegative. However, the differences are not statistically significant.

Conclusions: Although “silent” gonadotropinomas constitute a frequent subtype of pituitary adenomas, the “active” subtype (i.e. manifesting by gonadotropin excess) are rare (approx. 4% of all pituitary adenomas). Gonadotropinomas are difficult to diagnose before surgery. The measurement of gonadotropins including αSU is needed but often not sufficient for presurgical diagnosis.

Get Citation

Keywords

gonadotropinoma, follitropin, lutropin, α-subunit

About this article
Title

Blood serum concentrations of gonadotropins and α-subunit in patients with gonadotropinomas in relation to the immunoreactivity of pituitary adenoma

Journal

Endokrynologia Polska

Issue

Vol 69, No 5 (2018)

Pages

526-529

Published online

2018-08-03

DOI

10.5603/EP.a2018.0049

Pubmed

30074232

Bibliographic record

Endokrynologia Polska 2018;69(5):526-529.

Keywords

gonadotropinoma
follitropin
lutropin
α-subunit

Authors

Marek Pawlikowski (Łódź)
Maria Jaranowska
Jolanta Fryczak
Maciej Radek
Jacek Świętosławski
Jolanta Kunert-Radek
Katarzyna Winczyk

References (13)
  1. Snyder P. Gonadotroph cell adenomas of the pituitary. Endocrine Rev. 1985; 6(4): 552–563.
  2. Halupczok J, Bidzińska-Speichert B, Lenarcik-Kabza A, et al. Gonadotroph adenoma causing ovarian hyperstimulation syndrome in a premenopausal woman. Gynecol Endocrinol. 2014; 30(11): 774–777.
  3. Dahlqvist P, Koskinen LOD, Brännström T, et al. Testicular enlargement in a patient with a FSH-secreting pituitary adenoma. Endocrine. 2010; 37(2): 289–293.
  4. Trouillas J, Girod C, Sassolas G, et al. La cellule gonadotrope humaine normale et tumorale. Ann Endocrinol. 1990; 51: 54–64.
  5. Pawlikowski M, Kunert-Radek J, Radek A. Gonadotropinoma — a frequent subtype of the pituitary adenoma. Endokrynol Pol. 2000; 51: 77–81.
  6. Kunert-Radek J, Radek A, Gruszka A, et al. Immunohistochemical investigation of clinically nonfunctioning pituitary tumors as a prognostic factor of tumor recurrence. Proceedings of 12th Int Congress of Endocrinology. Lisbon. 31.VIII - 4.IX 2004: Medimond.
  7. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine. 2005; 28(1): 27–35.
  8. Pawlikowski M. Immunohistochemistry of pituitary tumours — clinical references [in polish]. Folia Medica Lodzensia. 2007; 34: 5–19.
  9. Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. 2014; 170(4): R121–R132.
  10. Snyder PJ. Gonadotroph cell pituitary adenomas. Endocrinol Metab Clin North Am. 1987; 16(3): 755–764.
  11. Chanson P, Brochier S. Non-functioning pituitary adenomas. J Endocrinol Invest. 2005; 28(11 Suppl International): 93–99.
  12. Gruszka A, Kunert-Radek J, Pawlikowski M. Serum alpha-subunit elevation after TRH administration: a valuable test in presurgical diagnosis of gonadotropinoma? Endokrynol Pol. 2005; 56(1): 14–18.
  13. Estepa A, Dastis M, Alia P, et al. Utility of alpha subunit determination after thyrotropin-releasing hormone stimulation as an indicator of gonadotropinoma persistence and/or recurrence. Endocrinol Nutr. 2008; 55(6): 253–258.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl